Exosomal miRNA-320a Is Released from hAMSCs and Regulates SIRT4 to Prevent Reactive Oxygen Species Generation in POI.
SIRT4
exosomes
human amniotic mesenchymal stem cells
miR-320a
oxidative stres
premature ovarian insufficiency
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
received:
08
03
2020
revised:
18
04
2020
accepted:
14
05
2020
pubmed:
9
6
2020
medline:
9
6
2020
entrez:
8
6
2020
Statut:
ppublish
Résumé
Human amniotic mesenchymal stem cells (hAMSCs) were previously shown to effectively rescue ovarian function in a premature ovarian insufficiency (POI) mouse model. The therapeutic mechanism of hAMSC-derived exosomes (hAMSC-Exos) is not fully understood. In this study, the therapeutic mechanism involved in exosomal microRNA-320a (miR-320a) and Sirtuin 4 (SIRT4) was investigated in POI mouse ovaries oocytes and human granulosa cells (hGCs) by fluorescence-activated cell sorting (FACS), hematoxylin and eosin (H&E) staining, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence experiments. hAMSC-Exos improved proliferation, inhibited apoptosis, and decreased the expression of SIRT4 and relative genes in POI hGCs and ovaries. hAMSC-Exos elevated ovarian function and prohibited SIRT4 expression in oogenesis. The therapeutic effects were attenuated when miR-320a was knocked down. hAMSC-Exos decreased the ROS levels in POI hGCs and oocytes and improved ovarian weight and litter size, except for the Exos
Identifiants
pubmed: 32506013
pii: S2162-2531(20)30139-6
doi: 10.1016/j.omtn.2020.05.013
pmc: PMC7272510
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37-50Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
J Am Heart Assoc. 2016 Jan 25;5(1):
pubmed: 26811168
Aging Cell. 2018 Aug;17(4):e12789
pubmed: 29845740
Fertil Steril. 2014 Dec;102(6):1751-61.e1
pubmed: 25241362
Hum Reprod Update. 2015 Nov-Dec;21(6):787-808
pubmed: 26243799
Nature. 2017 Aug 3;548(7665):52-57
pubmed: 28746310
Theranostics. 2018 Jan 1;8(1):169-184
pubmed: 29290800
Nat Immunol. 2014 Nov;15(11):1009-16
pubmed: 25329189
EMBO J. 2016 Mar 1;35(5):496-514
pubmed: 26834238
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1564-1569
pubmed: 29378963
Biol Reprod. 2011 Apr;84(4):775-82
pubmed: 21148108
Biomaterials. 2014 Jun;35(18):4888-900
pubmed: 24680661
J Mol Signal. 2010 Feb 18;5(1):1
pubmed: 20167101
Trends Endocrinol Metab. 2018 Nov;29(11):795-807
pubmed: 30078697
Aging (Albany NY). 2017 Oct 29;9(10):2163-2189
pubmed: 29081403
Stem Cell Res Ther. 2018 Aug 9;9(1):216
pubmed: 30092819
Stem Cell Res Ther. 2018 Mar 9;9(1):55
pubmed: 29523193
J Biol Chem. 2014 Jun 27;289(26):18239-57
pubmed: 24828505
Trends Mol Med. 2017 Apr;23(4):320-331
pubmed: 28285806
Stem Cells. 2017 Apr;35(4):851-858
pubmed: 28294454
Cell Physiol Biochem. 2018;45(4):1316-1332
pubmed: 29462806
Sci Rep. 2015 Mar 03;5:8689
pubmed: 25732513
Sci Rep. 2017 May 31;7(1):2552
pubmed: 28566720
Toxicol Sci. 2007 Jul;98(1):216-30
pubmed: 17434952
FASEB J. 2019 Apr;33(4):5535-5547
pubmed: 30649986
Aging (Albany NY). 2013 Nov;5(11):835-49
pubmed: 24296486
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33
pubmed: 20304794
FASEB J. 2012 Nov;26(11):4710-21
pubmed: 22767230
Stem Cell Res Ther. 2017 Jul 27;8(1):173
pubmed: 28750654
Antioxid Redox Signal. 2011 Oct 1;15(7):2067-79
pubmed: 20673161
Free Radic Biol Med. 2017 Sep;110:11-18
pubmed: 28499912
Nat Commun. 2016 Jun 15;7:11958
pubmed: 27302045
Hum Reprod. 2014 Sep;29(9):2006-17
pubmed: 24963165
Front Endocrinol (Lausanne). 2019 Jan 07;9:783
pubmed: 30666234
Oncogene. 2008 Sep 18;27(41):5527-41
pubmed: 18794886
Hum Reprod Update. 2018 May 1;24(3):267-289
pubmed: 29447380
Circulation. 2009 May 5;119(17):2357-2366
pubmed: 19380620
Stem Cell Res Ther. 2017 Nov 28;8(1):270
pubmed: 29179771